SecBot SecBot
DEFA14A ·Filed Mar 26, 2026

EW

Edwards Lifesciences Corp
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001099800-26-000018
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard proxy filing with no immediate trading implications. Traders should note the advisory vote on executive compensation as a potential indicator of shareholder sentiment, but the outcome is expected to be routine approval. Monitor for any future filings that may signal changes in strategy or governance.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.27
T+0 close · Mar 26, 2026 · via day close
Latest settled
+9.69%
T+60 · $86.95
Vs SPY
−6.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $79.27entry
  2. T+1 · 8mo ago +0.23%α +0.58% · $79.45
  3. T+5 · 8mo ago +2.32%α −1.54% · $81.11
  4. T+20 · 7mo ago +4.96%α −7.78% · $83.20
  5. T+60 · 5mo ago +9.69%α −6.00% · $86.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edwards Lifesciences Corp (EW) filed a DEFA14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing is a routine, management-sponsored solicitation requesting shareholder approval for the election of nine director nominees, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan. The document includes a stockholder presentation highlighting the company's innovation strategy and board composition.

Key Facts

  • The filing is a Definitive Additional Materials (DEFA14A) for the 2026 Annual Meeting.
  • The Board is requesting shareholder approval for four proposals: election of nine directors, advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan.
  • The document includes a Spring 2026 Stockholder Presentation with forward-looking statements about the company's strategy and innovation.
  • The board composition includes nine nominees with extensive experience in the medical technology industry.
  • The filing is routine and management-sponsored, with no indication of an activist campaign or contested election.

Financial Impact

No direct financial impact. The filing is a routine administrative document related to corporate governance.

governanceexecutive compensation

Risk Factors

  • The forward-looking statements in the presentation are subject to substantial risks and uncertainties, including competition, regulatory actions, and economic conditions, which could impact future performance.
  • While the current filing is routine, the advisory vote on executive compensation could become a point of contention if shareholder dissatisfaction grows in the future.

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001099800-26-000018
Document: 0001099800-26-000018-index-headers.html0001099800-26-000018
Document: 0001099800-26-000018-index.html0001099800-26-000018
Document: 0001099800-26-000018.txt0001099800-26-000018

Track record

27 reports on EW

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.94% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  3. Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  4. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  5. Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  7. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
  8. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
  9. Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
  10. Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026